CA2579753C - Lentivirus non integratif et non replicatif, preparation et utilisations - Google Patents
Lentivirus non integratif et non replicatif, preparation et utilisations Download PDFInfo
- Publication number
- CA2579753C CA2579753C CA2579753A CA2579753A CA2579753C CA 2579753 C CA2579753 C CA 2579753C CA 2579753 A CA2579753 A CA 2579753A CA 2579753 A CA2579753 A CA 2579753A CA 2579753 C CA2579753 C CA 2579753C
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- lentiviral
- lentivirus
- integrase
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000713666 Lentivirus Species 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 230000003362 replicative effect Effects 0.000 title claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 238000012546 transfer Methods 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 238000001727 in vivo Methods 0.000 claims abstract description 19
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 156
- 239000013598 vector Substances 0.000 claims description 151
- 102100034349 Integrase Human genes 0.000 claims description 89
- 239000013612 plasmid Substances 0.000 claims description 80
- 108010061833 Integrases Proteins 0.000 claims description 72
- 108700019146 Transgenes Proteins 0.000 claims description 57
- 230000035772 mutation Effects 0.000 claims description 44
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
- 230000010354 integration Effects 0.000 claims description 30
- 230000006870 function Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 210000004899 c-terminal region Anatomy 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 19
- 210000000653 nervous system Anatomy 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 238000001890 transfection Methods 0.000 claims description 13
- 230000003197 catalytic effect Effects 0.000 claims description 9
- 230000030147 nuclear export Effects 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000012223 nuclear import Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 101710091045 Envelope protein Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 6
- 101710188315 Protein X Proteins 0.000 claims description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 206010037742 Rabies Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 230000001228 trophic effect Effects 0.000 claims description 5
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 4
- 241000725171 Mokola lyssavirus Species 0.000 claims description 4
- 208000010094 Visna Diseases 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 230000008676 import Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010010144 Completed suicide Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 239000002858 neurotransmitter agent Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 2
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 2
- 108091027981 Response element Proteins 0.000 claims description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 7
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 210000000496 pancreas Anatomy 0.000 abstract description 4
- 230000007170 pathology Effects 0.000 abstract description 4
- 230000010076 replication Effects 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 210000005228 liver tissue Anatomy 0.000 abstract description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 81
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 81
- 239000005090 green fluorescent protein Substances 0.000 description 80
- 230000014509 gene expression Effects 0.000 description 52
- 238000010361 transduction Methods 0.000 description 39
- 230000026683 transduction Effects 0.000 description 39
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 16
- 108700004025 env Genes Proteins 0.000 description 14
- 239000000049 pigment Substances 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 101150104383 ALOX5AP gene Proteins 0.000 description 7
- 101710121417 Envelope glycoprotein Proteins 0.000 description 7
- 101100236114 Mus musculus Lrrfip1 gene Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- HWOLQKJPMRZMEX-PJKMHFRUSA-N diazonio-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]azanide Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(N=[N+]=[N-])O[C@H](CO)[C@@H](O)C1 HWOLQKJPMRZMEX-PJKMHFRUSA-N 0.000 description 7
- 210000001577 neostriatum Anatomy 0.000 description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 108091008695 photoreceptors Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 5
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 5
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 108700005077 Viral Genes Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- -1 nave Proteins 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 108700004030 rev Genes Proteins 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150031523 4a gene Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102220638993 Beta-enolase_H16C_mutation Human genes 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 108010024777 Mating Factor Receptors Proteins 0.000 description 1
- 102220485636 Mitogen-activated protein kinase 15_K42A_mutation Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102220497402 Oxysterol-binding protein-related protein 3_K71A_mutation Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102220509593 Small integral membrane protein 10_H51A_mutation Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102220635504 Vacuolar protein sorting-associated protein 33A_D41A_mutation Human genes 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 102220036548 rs140382474 Human genes 0.000 description 1
- 102200052245 rs199469625 Human genes 0.000 description 1
- 102220128858 rs200860772 Human genes 0.000 description 1
- 102220139188 rs35702995 Human genes 0.000 description 1
- 102220237139 rs376184349 Human genes 0.000 description 1
- 102220045124 rs587781846 Human genes 0.000 description 1
- 102200155054 rs80358230 Human genes 0.000 description 1
- 102220146256 rs886059153 Human genes 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0407017A FR2872170B1 (fr) | 2004-06-25 | 2004-06-25 | Lentivirus non interactif et non replicatif, preparation et utilisations |
| FR0407017 | 2004-06-25 | ||
| PCT/FR2005/001604 WO2006010834A1 (fr) | 2004-06-25 | 2005-06-24 | Lentivirus non integratif et non replicatif, preparation et utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2579753A1 CA2579753A1 (fr) | 2006-02-02 |
| CA2579753C true CA2579753C (fr) | 2015-04-14 |
Family
ID=34948183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2579753A Expired - Fee Related CA2579753C (fr) | 2004-06-25 | 2005-06-24 | Lentivirus non integratif et non replicatif, preparation et utilisations |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8119119B2 (enExample) |
| EP (1) | EP1761635B1 (enExample) |
| JP (1) | JP4861314B2 (enExample) |
| CN (1) | CN101023177A (enExample) |
| AT (1) | ATE524554T1 (enExample) |
| AU (1) | AU2005266221B2 (enExample) |
| CA (1) | CA2579753C (enExample) |
| FR (1) | FR2872170B1 (enExample) |
| IL (1) | IL179740A0 (enExample) |
| WO (1) | WO2006010834A1 (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2007091066A1 (en) * | 2006-02-07 | 2007-08-16 | Ucl Business Plc | Applications of non-integrating lentiviral vectors |
| PL2020444T3 (pl) * | 2007-08-03 | 2017-10-31 | Pasteur Institut | Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek |
| MX2010001379A (es) | 2007-08-03 | 2010-06-08 | Pasteur Institut | Vectores de tranferencia de gen lentiviral y sus aplicaciones medicinales. |
| AU2013203404B2 (en) * | 2007-08-03 | 2016-10-13 | Centre National De La Recherche Scientifique (Cnrs) | Lentiviral gene transfer vectors and their medicinal applications |
| WO2009054985A1 (en) | 2007-10-25 | 2009-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
| CN102046785A (zh) * | 2008-03-28 | 2011-05-04 | 维克西斯公司 | 基于慢病毒的免疫原性载体 |
| WO2009131706A1 (en) * | 2008-04-26 | 2009-10-29 | Yung-Nien Chang | Site-specific-integration lentiviral vectors |
| RU2012140691A (ru) * | 2009-03-13 | 2014-03-27 | Лентиген Корпорейшен | Вакцины на основе неинтегрирующегося ретровирусного вектора |
| EP2419511B1 (en) | 2009-04-09 | 2018-01-17 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| EP2385107B1 (en) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
| WO2012152912A1 (en) | 2011-05-12 | 2012-11-15 | Newvectys | Genetically modified pig as a cancer prone model |
| ES2651922T3 (es) | 2011-11-08 | 2018-01-30 | Institut Pasteur | Polipéptidos de afinidad elevada para MAST2 y usos de los mismos |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| MX362699B (es) | 2012-03-30 | 2019-02-01 | Immune Design Corp | Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign. |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| JP2016501531A (ja) | 2012-12-12 | 2016-01-21 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化 |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| JP6738729B2 (ja) * | 2013-06-17 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化 |
| JP6625971B2 (ja) | 2013-06-17 | 2019-12-25 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化 |
| EP4245853A3 (en) | 2013-06-17 | 2023-10-18 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| MX374532B (es) | 2013-06-17 | 2025-03-06 | Broad Inst Inc | Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos. |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| KR20160030187A (ko) | 2013-06-17 | 2016-03-16 | 더 브로드 인스티튜트, 인코퍼레이티드 | 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도 |
| WO2015040063A1 (en) * | 2013-09-17 | 2015-03-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Lentiviral vectors having a mutated integrase protein and uses thereof |
| EP2878667A1 (en) | 2013-11-29 | 2015-06-03 | Institut Pasteur | TAL effector means useful for partial or full deletion of DNA tandem repeats |
| KR102805572B1 (ko) | 2013-12-12 | 2025-05-09 | 더 브로드 인스티튜트, 인코퍼레이티드 | 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용 |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| EP3653703A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| BR112016013207A2 (pt) | 2013-12-12 | 2017-09-26 | Massachusetts Inst Technology | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| PL3689899T3 (pl) | 2014-04-25 | 2022-01-31 | 2Seventy Bio, Inc. | Chimeryczne receptory antygenowe promotora mnd |
| ES2800906T3 (es) | 2014-04-25 | 2021-01-05 | Bluebird Bio Inc | Métodos mejorados para producir terapias celulares adoptivas |
| SG10202108458XA (en) | 2014-06-06 | 2021-09-29 | 2Seventy Bio Inc | Improved t cell compositions |
| KR102523934B1 (ko) | 2014-07-24 | 2023-04-20 | 2세븐티 바이오, 인코포레이티드 | Bcma 키메릭 항원 수용체 |
| EP3031923A1 (en) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
| WO2016094304A2 (en) | 2014-12-12 | 2016-06-16 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| AU2015369725A1 (en) | 2014-12-24 | 2017-06-29 | Massachusetts Institute Of Technology | CRISPR having or associated with destabilization domains |
| SG10201912329YA (en) | 2015-06-18 | 2020-02-27 | Broad Inst Inc | Crispr Enzyme Mutations Reducing Off-Target Effects |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| US10701165B2 (en) | 2015-09-23 | 2020-06-30 | Sensoriant, Inc. | Method and system for using device states and user preferences to create user-friendly environments |
| WO2017060662A1 (en) * | 2015-10-07 | 2017-04-13 | The Secretary Of State For Health | Method for providing a control for use in a screen for pathogenic virus |
| US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
| CN109311963A (zh) | 2016-04-14 | 2019-02-05 | 蓝鸟生物公司 | 救助嵌合抗原受体系统 |
| WO2017214938A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 特异促进 bace1 基因高表达的慢病毒表达载体及应用 |
| EP3500696A4 (en) | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE |
| CA3034782A1 (en) | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| ES2952525T3 (es) | 2016-09-08 | 2023-11-02 | 2Seventy Bio Inc | Variantes de endonucleasa homing PD-1, composiciones y métodos de uso |
| JP7060591B2 (ja) | 2016-10-17 | 2022-04-26 | ２セブンティ バイオ インコーポレイテッド | ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法 |
| MA46723A (fr) | 2016-11-04 | 2019-09-11 | Bluebird Bio Inc | Compositions de lymphocytes t car anti-bcma |
| MX2019005724A (es) | 2016-11-17 | 2019-07-08 | Bluebird Bio Inc | Conversor de se?ales de tgfbeta. |
| KR20190089988A (ko) * | 2016-12-06 | 2019-07-31 | 블루버드 바이오, 인코포레이티드. | I형 점액다당류증에 대한 유전자 요법 |
| CA3046080A1 (en) * | 2016-12-06 | 2018-06-14 | Bluebird Bio, Inc. | Gene therapy for mucopolysaccharidosis, type ii |
| EP3357506A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host |
| EP3357504A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity |
| AU2018221730B2 (en) | 2017-02-15 | 2024-06-20 | Novo Nordisk A/S | Donor repair templates multiplex genome editing |
| JP7191042B2 (ja) | 2017-05-25 | 2022-12-16 | ２セブンティ バイオ インコーポレイテッド | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
| EP3502260A1 (en) | 2017-12-22 | 2019-06-26 | Oxford BioMedica (UK) Limited | Retroviral vector |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| DE102018010282A1 (de) | 2018-01-17 | 2019-07-18 | Immatics US, Inc. | Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren |
| KR102887853B1 (ko) | 2018-06-14 | 2025-11-19 | 리제너론 파마슈티칼스 인코포레이티드 | Cd79a 키메라 항원 수용체 |
| CN112689516A (zh) | 2018-07-11 | 2021-04-20 | 细胞基因公司 | 抗bcma嵌合抗原受体的用途 |
| KR20210102870A (ko) | 2018-08-30 | 2021-08-20 | 테나야 테라퓨틱스, 인코포레이티드 | 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍 |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| AU2019397364B8 (en) | 2018-12-10 | 2025-08-07 | Novo Nordisk A/S | Homing endonuclease variants |
| KR20210104772A (ko) | 2018-12-14 | 2021-08-25 | 블루버드 바이오, 인코포레이티드. | 이량체화제로 조절된 면역수용체 복합체 |
| WO2020205889A1 (en) | 2019-04-01 | 2020-10-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| WO2021007515A1 (en) | 2019-07-11 | 2021-01-14 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
| EP3770264A1 (en) | 2019-07-22 | 2021-01-27 | Genethon | Precise integration using nuclease targeted idlv |
| CN114401989B (zh) | 2019-09-20 | 2024-02-09 | 上海吉倍生物技术有限公司 | 靶向bcma的抗体及嵌合抗原受体 |
| JP2022554351A (ja) | 2019-11-05 | 2022-12-28 | セルジーン コーポレイション | 抗ｂｃｍａキメラ抗原受容体の使用法 |
| KR20220097492A (ko) | 2019-11-12 | 2022-07-07 | 옥스포드 바이오메디카(유케이) 리미티드 | 생산 시스템 |
| EP4103723A1 (en) | 2020-02-13 | 2022-12-21 | Oxford BioMedica (UK) Limited | Production of lentiviral vectors |
| CN115667534A (zh) | 2020-03-13 | 2023-01-31 | 牛津生物医学（英国）有限公司 | 慢病毒载体 |
| WO2021212279A1 (zh) * | 2020-04-20 | 2021-10-28 | 广东东阳光药业有限公司 | 慢病毒的滴度提高型转移质粒 |
| CN114807228B (zh) * | 2020-04-27 | 2023-12-15 | 北京化工大学 | 一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法 |
| GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
| US11781156B2 (en) | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| EP3984548A1 (en) | 2020-10-16 | 2022-04-20 | Institut Pasteur | Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host |
| KR20230113755A (ko) | 2020-11-04 | 2023-08-01 | 셀진 코포레이션 | 선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법 |
| GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
| EP4272002A1 (en) | 2020-12-04 | 2023-11-08 | Celgene Corporation | Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors |
| AU2022233021A1 (en) | 2021-03-12 | 2023-09-21 | Institut Pasteur | Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host |
| CA3214280A1 (en) | 2021-04-16 | 2022-10-20 | Julie Ann RYTLEWSKI | T cell therapy in patients who have had prior stem cell transplant |
| KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
| GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
| GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| IL316032A (en) | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| CA3246384A1 (en) | 2022-04-13 | 2023-10-19 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | TREATMENT OF NEUROMUSCULAR DISEASES BY GENE THERAPY EXPRESSING THE KLOTHO PROTEIN |
| JP2025516629A (ja) | 2022-05-11 | 2025-05-30 | セルジーン コーポレーション | Ｔ細胞療法に関連する方法および使用、ならびにその生成 |
| IL317172A (en) | 2022-05-26 | 2025-01-01 | Regeneron Pharma | Lentiviral vector maintenance vehicles and uses thereof |
| GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
| CN120202017A (zh) | 2022-10-21 | 2025-06-24 | 赛拉福柯蒂斯公司 | 表达选自denv、zikv及yfv的黄病毒的非结构抗原、诱导宿主中保护性cd8+t细胞免疫的多核苷酸及慢病毒载体 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025153530A1 (en) | 2024-01-16 | 2025-07-24 | Novo Nordisk A/S | Albumin-targeted endonucleases, compositions, and methods of use |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| ES2324745T3 (es) * | 1996-02-21 | 2009-08-13 | Genetic Immunity Kft. | Procedimientos y composiciones para la inmunizacion genetica protectora y terapeutica. |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6365150B1 (en) | 1998-05-13 | 2002-04-02 | Genetix Pharmaceuticals, Inc. | Lentiviral packaging cells |
| EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| WO2000072886A1 (en) * | 1999-05-26 | 2000-12-07 | Dana-Farber Cancer Institute, Inc. | Episomally replicating lentiviral vectors |
| ATE351916T1 (de) | 1999-10-12 | 2007-02-15 | Pasteur Institut | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten |
| NZ525283A (en) * | 2000-09-22 | 2008-06-30 | Virxsys Corp | Conditionally replicating vectors, methods for their production and use |
| FR2825372B1 (fr) | 2001-06-01 | 2004-06-18 | Centre Nat Rech Scient | Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus |
| US20070042494A1 (en) * | 2005-05-31 | 2007-02-22 | Tal Kafri | Heterologous retroviral packaging system |
-
2004
- 2004-06-25 FR FR0407017A patent/FR2872170B1/fr not_active Expired - Fee Related
-
2005
- 2005-06-24 EP EP05779704A patent/EP1761635B1/fr not_active Expired - Lifetime
- 2005-06-24 AT AT05779704T patent/ATE524554T1/de not_active IP Right Cessation
- 2005-06-24 WO PCT/FR2005/001604 patent/WO2006010834A1/fr not_active Ceased
- 2005-06-24 JP JP2007517365A patent/JP4861314B2/ja not_active Expired - Fee Related
- 2005-06-24 AU AU2005266221A patent/AU2005266221B2/en not_active Ceased
- 2005-06-24 CA CA2579753A patent/CA2579753C/fr not_active Expired - Fee Related
- 2005-06-24 US US11/628,534 patent/US8119119B2/en not_active Expired - Fee Related
- 2005-06-24 CN CNA2005800209389A patent/CN101023177A/zh active Pending
-
2006
- 2006-11-30 IL IL179740A patent/IL179740A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005266221A1 (en) | 2006-02-02 |
| EP1761635A1 (fr) | 2007-03-14 |
| JP4861314B2 (ja) | 2012-01-25 |
| EP1761635B1 (fr) | 2011-09-14 |
| JP2008503230A (ja) | 2008-02-07 |
| IL179740A0 (en) | 2007-05-15 |
| ATE524554T1 (de) | 2011-09-15 |
| WO2006010834A1 (fr) | 2006-02-02 |
| AU2005266221B2 (en) | 2010-06-10 |
| FR2872170A1 (fr) | 2005-12-30 |
| US8119119B2 (en) | 2012-02-21 |
| CN101023177A (zh) | 2007-08-22 |
| US20080089863A1 (en) | 2008-04-17 |
| FR2872170B1 (fr) | 2006-11-10 |
| CA2579753A1 (fr) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2579753C (fr) | Lentivirus non integratif et non replicatif, preparation et utilisations | |
| CA2326719C (fr) | Utilisation de sequences d'adn de structure triplex pour le transfert de sequences nucleotidiques | |
| CA2183151C (fr) | Systeme hote-vecteur utilisable en therapie genique | |
| CA2251027C (fr) | Particules virales defectives vaccinales obtenues in vivo ou ex vivo | |
| JP2008303215A (ja) | ベクターシステム | |
| EP0912723A1 (fr) | Lignees d'encapsidation hautement productrices | |
| FR2741358A1 (fr) | Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn | |
| EP1778295A1 (de) | Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren | |
| EP2776568B1 (fr) | Cassette d'expression inductible et ses utilisations | |
| CA2448947C (fr) | Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus | |
| DE60313743T2 (de) | Mit influenzavirus-hämagglutinin und influenza m2 pseudotypisierte retrovirusvektoren zur zuführung von genen | |
| FR2762615A1 (fr) | Nouveau site interne d'entree des ribosomes et vecteur le contenant | |
| US20090233988A1 (en) | Therapeutic Agents for Diseases Associated With Apoptotic Degeneration in Ocular Tissue Cells That Use SIV-PEDF Vectors | |
| DE602004013165T2 (de) | Chimärisches vektorsystem | |
| JP2006502240A (ja) | ベクター系 | |
| EP1006123A2 (fr) | Protéines d'enveloppe, methodes et utilisations | |
| WO2025157808A1 (fr) | Production de vecteurs toxiques | |
| WO2025157813A1 (fr) | Production de vecteurs toxiques | |
| FR2652504A1 (fr) | Composition immunisante et procede de preparation. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |